Navigation Links
OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation

6. Empatic was associated with significant weight reduction through 48 weeks of treatment but also early discontinuations due to adverse events in approximately 37% of study participants. Zonisamide appeared to be the principal contributing factor, as a similar rate of discontinuations was evident among subjects receiving zonisamide IR therapy alone. Orexigen, in partnership with PharmaDirections, Inc. developed the proprietary SR formulation of zonisamide with the objective of improving its overall tolerability.

"We are excited that our novel, sustained release formulation of zonisamide was significantly better tolerated than the existing generic IR formulation. This is an important consideration in conditions such as obesity that often require longer-term maintenance therapy. Based on these results, we are eagerly awaiting the outcome of our ongoing 24 week Phase IIb multi-center study of Empatic, which incorporates our proprietary formulation of zonisamide SR," said Gary Tollefson, M.D., Ph.D., Orexigen's President and CEO.

About Orexigen(TM) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:3/30/2015)... , March 30, 2015  Amgen (NASDAQ: AMGN ) ... conference at 9:05 a.m. ET on Thursday, April 2, 2015, ... York City . Scott Foraker , vice president ... the conference. Live audio of the presentation can be accessed ... under Investors. A replay of the webcast will also be ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/dn2ldn/computer_aided ) ... Aided Detection (CAD) - Global Strategic Business Report" ... estimates and forecasts are provided for the period ... is provided for these markets. Market data and ... Company profiles are primarily based on public domain ...
(Date:3/30/2015)... 30, 2015  Uroplasty, Inc. (NASDAQ: UPI ) ... have voted at the special meeting of each ... announced agreement and plan of merger between the ... the outcome of today,s special meetings, and I ... approving the merger agreement," said Rob Kill ...
Breaking Medicine Technology:Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference 2Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 2Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 3Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 4Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4
... PRINCETON, N.J. , June 21 Celator Pharmaceuticals ... Inc. (Nasdaq: CEPH). The research agreement provides for the utilization of ... program at Cephalon. , ... "We are pleased that work with this research program ...
... Qatar , June 21 One of the leading cancer ... in the region to introduce fast and efficient RapidArc® radiotherapy treatments from ... , has treated nine brain cancer, prostate cancer and head & neck ... now plans to roll out the technology for many more indications. , ...
Cached Medicine Technology:Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 2Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 3Al Amal Hospital in Qatar Commences Treatments Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Al Amal Hospital in Qatar Commences Treatments Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3
(Date:3/30/2015)... 2015 Textile Exchange, a global nonprofit ... today announced the latest version of its Responsible ... that can be applied to any waterfowl-based supply chain ... to end product. The goal of the RDS is ... and to enable traceability so that products can be ...
(Date:3/30/2015)... “We are pleased to announce three volunteer pilot ... in Los Angeles,” said Mark Wolper, Chair of Endeavor ... a nationwide call for nominations. , The awards ... Durden with LightHawk and Stephen Purello of Angel Flight ... will receive a $15,000 contribution from the Endeavor Awards ...
(Date:3/30/2015)... On March 11, 2015, Elle Magazine, in an article ... new treatment options for dealing with stubborn, unwanted fat. Two ... product. The other three technologies use devices to deliver ultrasound ... cold ( CoolSculpting ) to kill fat cells. (see: goo.gl/NmaB4q) ... to permanently remove unwanted fat," says Dr. Simon Ourian, Medical ...
(Date:3/30/2015)... 2015 Innovaacom, a leading provider of ... announced it is expanding its services into Asia in ... of the world comes at a time when Asia’s ... for better healthcare. A rapidly growing aging population and ... advances in medicine in Asia. “We are excited to ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 According to ... ), the hernia repair market will continue to dominate ... is occurring primarily due to increasing numbers of ventral ... them. , “The significantly large market share represented ... generally high ASP. We’re seeing a growing use of ...
Breaking Medicine News(10 mins):Health News:Responsible Down Standard 2.0 Released 2Health News:Responsible Down Standard 2.0 Released 3Health News:2015 Endeavor Awards Recipients Announced 2Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Innovaacom Expands Services and Medical Education Programs into Asia 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 3
... The United States,Agency for International Development (USAID) is ... solution that reduces the risk of,diarrhea. Sur,Eau is ... chlorine solution can be added to water immediately ... principally young children and,people living with HIV and ...
... April 25 Torchmark,Corporation (NYSE: TMK ) announced ... of $.14 per share on all of the outstanding ... the close of business of the,Company,s transfer agent on ... 1, 2008., Torchmark Corporation is a holding company ...
... April 25 AMDL, Inc. (Amex:,ADL), an international ... and diagnostic products in China, announced,today that a ... AMDL has been posted,by analyst Lauren Rudd at ... price of $23 and a Buy Recommendation., ...
... G.,Rendell said national "Cover the Uninsured Week" is the ... Basic Care (PA ABC), which,passed the House of Representatives ... care to hundreds of thousands of uninsured,Pennsylvanians., "Cover ... "Every day we hear from Pennsylvanians who are ...
... TV Game Show Host Spark Controversy, LOS ANGELES, ... television game show "The Price Is Right," recently spoke ... group formed to,support responsible dog ownership. The group has ... went into effect this month in Los,Angeles County (isn,t ...
... eye surgery, but complaints show it may not be for ... Tiger Woods lauds vision-correcting LASIK surgery as "life changing." NASA ... military says it has been performed on 112,500 military personnel, ... and complications of this elective surgery being lost in this ...
Cached Medicine News:Health News:Disinfecting Water Saves Lives in Rwanda 2Health News:The Rudd Report, Dated April 18, 2008, Updates AMDL's Recent Achievements 2Health News:Governor Rendell Says 'Cover the Uninsured Week' is Perfect Time for Action on Program to Provide Access to Health Care for Uninsured 2Health News:Governor Rendell Says 'Cover the Uninsured Week' is Perfect Time for Action on Program to Provide Access to Health Care for Uninsured 3Health News:Governor Rendell Says 'Cover the Uninsured Week' is Perfect Time for Action on Program to Provide Access to Health Care for Uninsured 4Health News:Governor Rendell Says 'Cover the Uninsured Week' is Perfect Time for Action on Program to Provide Access to Health Care for Uninsured 5Health News:Governor Rendell Says 'Cover the Uninsured Week' is Perfect Time for Action on Program to Provide Access to Health Care for Uninsured 6Health News:Bob Barker's 'Right' to Free Speech Comes with a 'Price' 2Health News:FDA Examines 'Quality of Life' for LASIK Patients 2Health News:FDA Examines 'Quality of Life' for LASIK Patients 3
AllMeds was the first specialty-specific Electronic Medical Record for Neurosurgery. Instead of trying to force a general-purpose EMR into your practice, AllMeds starts with clinical content from Neu...
... Optical dispensing is a part of about 40% ... have created a point of sale system. Optical ... program or it can be integrated to the ... national Frames database. Glasses prescriptions, if connected ...
... tasks such as prescription writing, referral letters, ... office will be ,able to add more ... increase staff., Based on the exam documentation ... will recommend the appropriate E&M ,code for ...
... Access your patients' electronic medical ... CardioChart. As a Web-enabled software ... pull up a patient's cardiology ... the hospital intranet. CardioChart displays ...
Medicine Products: